Triple-negative breast cancer (TNBC) lacks the estrogen receptor (ER), progesterone receptor (PR), and HER2 receptor and therefore does not respond to endocrine therapy or anti-Her2 therapy, resulting in poor prognosis1. This evidence concerns the gene PGR and triple-negative breast carcinoma.